Travere Therapeutics
NASDAQ: TVTX1 known investors
Travere Therapeutics develops and delivers therapies for rare kidney and metabolic diseases, with a pipeline including potential first-in-class treatments for conditions such as classical homocystinuria and immune-mediated rare kidney diseases. The company also supports initiatives to improve diagnosis, access, and equity in rare disease care for patients and their families.
Founders & leadership
ED
Eric DubeinChief Executive Officer and Director
Investors · 1
In the news
Frequently asked questions
- What does Travere Therapeutics do?
- Travere Therapeutics develops and delivers therapies for rare kidney and metabolic diseases, with a pipeline including potential first-in-class treatments for conditions such as classical homocystinuria and immune-mediated rare kidney diseases. The company also supports initiatives to improve diagnosis, access, and equity in rare disease care for patients and their families.
- Who are Travere Therapeutics's investors?
- Travere Therapeutics's investors include Ligand Pharmaceuticals.